SR31-SA3,1,5
3"Whereas, pharmaceutical companies' after-tax profits, after expenditures for
4research and development, averaged 17 percent from 1994 to 1998, compared with
55 percent for all other industries; and
SR31-SA3,1,76
Whereas, pharmaceutical companies spent $15.7 billion in 2000 on product
7promotion despite being protected from competition by current law; and
SR31-SA3,1,108
Whereas, pharmaceutical companies from 1993 to 1996 paid an average
9effective tax rate of 16.2 percent, compared to all other major industries, which paid
10an average effective tax rate of 27.3 percent; and".